Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 Trial
(NASDAQ: LOXO) Delayed: 234.80 --0 (-0%)
Previous Close $234.80    52 Week High $35.00 
Open $5.92    52 Week Low $16.36 
Day High $234.80    P/E N/A 
Day Low $234.80    EPS $0.00 
Volume 1,125,528